New insider Alves Sandra Isabelle Barros claimed ownership of 25,522 shares (SEC Form 3)
$RPTX
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 03/31/2025 |
3. Issuer Name and Ticker or Trading Symbol
Repare Therapeutics Inc. [ RPTX ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Shares | 25,522(1) | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Employee Stock Option (right to buy) | (2) | 03/09/2030 | Common Shares | 57,736 | $6.79 | D | |
| Employee Stock Option (right to buy) | (2) | 02/08/2031 | Common Shares | 21,565 | $36.91 | D | |
| Employee Stock Option (right to buy) | (3) | 01/17/2032 | Common Shares | 38,645 | $15.63 | D | |
| Employee Stock Option (right to buy) | (4) | 01/29/2033 | Common Shares | 18,600 | $12.42 | D | |
| Employee Stock Option (right to buy) | (5) | 02/28/2034 | Common Shares | 14,300 | $6.95 | D | |
| Employee Stock Option (right to buy) | (6) | 03/03/2035 | Common Shares | 26,000 | $1.17 | D | |
| Explanation of Responses: |
| 1. 14,700 Common Shares represent restricted stock unit ("RSU") grants. 3,433 RSUs will vest on January 30, 2026; 4,767 RSUs will vest in two equal installments commencing on March 1, 2026; and 6,500 RSUs will vest in three equal installments commencing on March 4, 2026, subject to Reporting Person continuing to provide service through each such date. |
| 2. Fully vested and exerciseable. |
| 3. Twenty-five percent (25%) of the shares subject to the option vested on January 18, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or will vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. |
| 4. Twenty-five percent (25%) of the shares subject to the option vested on January 30, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or will vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. |
| 5. Twenty-five percent (25%) of the shares subject to the option vested on March 1, 2025, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or will vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. |
| 6. 13,000 shares subject to the option will vest on March 4, 2026. With respect to the remaing 13,000 shares subject to the option, twenty-five percent (25%) will vest on March 4, 2026, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. |
| /s/ Steve Forte, Attorney-in-Fact | 04/29/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||